Human leukocyte antigen class-Ⅱ DRB1 alleles and Giardia lamblia infection in children: A case-control study

Objective:To compare the genotype frequencies of HLA class-ⅡDRB1 alleles in Giardia(G.)lamblia-infected children.Methods:A total of 490 Egyptian children aged 2-16 years were subjected to microscopic stool examination to detect G.lamblia infection,and to exclude other intestinal pathogens.On the basis of their microscopic findings,a group of 80 children were chosen as giardiasis cases,another 80 children were confirmed as Giardia free control group by immunochromatographic test,and the remaining children were excluded.Both giardiasis and control groups were then subjected to blood examination to identify their genetic type of HLA-DRB1 alleles.Results:HLA class-ⅡDRB1*03:01 and DRB1*13:01 alleles were significantly associated with G.lamblia infection(P<0.001 for each variable).On the other hand,HLA class-ⅡDRB1*04:02,DRB1*10:01,DRB1*14:01 and DRB1*15:01 alleles were significantly demonstrated in Giardia free children.However,other HLA-DRB1 alleles did not show any significant association with giardiasis.Conclusions:HLA class-ⅡDRB1*03,DRB1*13,DRB1*04,DRB1*10,DRB1*14 and DRB1*15 alleles may be involved in the establishment of host immune response to G.lamblia infection.

Specific HLA-DQB1 alleles associated with risk for development of hepatocellular carcinoma:A meta-analysis

AIM:To evaluate the association of human leukocyte antigen(HLA)-DQB1 alleles with hepatocellular carcinoma(HCC) through meta-analysis of published data.METHODS:Case-control studies on HLA-DQB1 allele association with HCC published up to January 2010 were included in the analyses.The odds ratios(ORs) of HLADQB1 allele distributions in HCC patients were analyzed and compared with healthy controls.The meta-analysis software REVMAN 5.0 was applied for investigating heterogeneity among individual studies and for summarizing all the studies.A meta-analysis was performed using fixed-effect or random-effect methods,depending on the absence or presence of significant heterogeneity.Seven case-control studies containing 398 cases and 594 controls were included in the final analysis.RESULTS:Among the five family alleles,two(DQB1*02 and DQB1*03) were found to be significantly associated with the risk of HCC.The combined OR for the association of DQB1*02 and DQB1*03 allele with the risk for HCC was 1.78(95% CI:1.05-3.03,P = 0.03) and 0.65(95% CI:0.48-0.89,P = 0.007),respectively.Among the 13 specific alleles,two(DQB1*0502 and DQB1*0602) were significantly associated with risk of HCC.The combined OR for the association of DQB1*0502 and DQB1*0602 allele with the risk for HCC was 1.82(95% CI:1.14-2.92,P = 0.01) and 0.58(95% CI:0.36-0.95,P = 0.03),respectively.No significant association was established for other HLA-DQB1 family alleles and specific alleles.CONCLUSION:Our results support the hypothesis that specific HLA-DQB1 allele families and alleles might influence the susceptibility or resistance to HCC,although it needs further investigations.

HLA-DRB1~＊14等位基因对阿德福韦酯治疗HBeAg阳性慢性乙型肝炎疗效的影响

目的探讨HLA-DRB1*14等位基因对阿德福韦酯(ADV)治疗HBeAg阳性慢性乙型肝炎疗效的影响。方法采用序列特异性引物聚合酶链反应技术(PCR-SSP)检测65例HBeAg阳性慢性乙型肝炎患者(病例组)和70例健康人(对照组)等位基因HLA-DRBI*14,比较阿德福韦酯治疗有效组和无效组中HLA-DRB1*14等位基因阳性率。结果病例组、对照组HLA-DRB1*14等位基因阳性率分别为15.7%和15.4%,两组差异无统计学意义(P>0.05);治疗有效组HLA-DRB1*14等位基因阳性率为15.6%,无效组为15.2%,两组差异无统计学意义(P>0.05)。结论 HLA-DRB1*14等位基因在HBeAg阳性慢性乙型肝炎患者和健康人群的分布基本一致,该基因对阿德福韦酯治疗HBeAg阳性慢乙肝疗效无明显影响。

Effect of Early Intensive Insulin Therapy on Immune Function of Aged Patients with Severe Trauma

This study examined the effect of intensive insulin therapy on immune function and inflammatory factors at the early phase after severe trauma. At day 1, 3, 5, 7 after admission, subsets of CD4＋ helper T lymphocytes （Th1/Th2） and human leukocyte antigen （HLA）-DR expression on CD14＋ monocytes were flow cytometrically measured. Levels of cytokines, including tumor necrosis factor-alpha （TNF-α）, interleukin-6 （IL-6）, interleukin-10 （IL-10） and other immunity markers, such as IgA, IgG, IgM, C3, C4 and C reaction protein （CRP） were examined in two groups. The results showed that TNF-α, IL-6 and CRP levels in the intensive insulin therapy group were significantly lower than those in the conventional therapy group, whereas IL-10 levels were substantially increased after intensive insulin therapy. C3 level at day 3, 5, 7 and C4 levels at day 5, 7 were lower in the intensive therapy group than in the conventional therapy group. Th1/Th2 ratios decreased gradually over time in both groups, and were much lower at day 3, 5, 7 in intensive therapy group. There were significant differences among day 3 to day 7 after admission in HLA-DR expression in CD14＋ monocytes. It was concluded that the intensive insulin therapy could decrease pro-inflammatory cytokines and increase anti-inflammatory cytokines in the elderly suffering from severe trauma, at the same time, with complement recovery being delayed. Moreover, intensive insulin therapy promoted immune suppression and, therefore, measures need be taken to address the issue.

人类白细胞抗原A和DRB1基因与1型糖尿病的相关性研究

目的研究江苏地区人类白细胞抗原（HL4）-A和月出-DRBl基因频率及单倍型与1型糖尿病的相关性。方法于2008至2009年在江苏省江阴市和南京市选择自发酮症急性起病、依赖胰岛素治疗的1型糖尿病门诊或住院患者51例（1型糖尿病组），其中男27例，女24例，平均发病年龄（14±9）岁。另以2002至2006年登记加入中华骨髓库江苏分库的汉族无关骨髓捐献志愿者HLA分型资料20248份为对照。从受试者外周血中提取细胞基因组DNA，利用聚合酶链反应-寡核苷酸探针序列特异性引物技术进行HLA—A和月似-DRBl基因分型，应用Arlequin软件分析计算单倍型频率及连锁不平衡情况，通过卡方检验等比较组间基因频率、单倍型频率及疾病相关性分析。结果HLA-A点频率最高的为A＊02和A＊24，HLA-DRBl位点频率最高的为DRBl＊09。与对照组相比，1型糖尿病组HLA—A＊3[6．86％（7／102）比2．43％（984／40496），X^2=8．40，P〈0．01，比值比（OR）=3．00]、A＊24[27．45％（28／102）比16．79％（6799／40496），X^2=8．27，P〈0．01，OR=1．87]和DRBl＊09[32．35％（33／102）比16．15％（6540／40496），X^2=19．69，P〈0．01，OR=2．47]、DRBl＊03[15．69％（16／102）比4．76％（1927／40496），X^2=26．66，P〈0．01，OR=3．69]频率显著升高。A＊01-DRBl＊03在连锁不平衡分析中为1型糖尿病组所特有。结论检测出位点A＊03、A＊24及DR03、DR09对1型糖尿病的易患性，发现3个有易患作用的A—DR单倍型，观察到与1型糖尿病关联的祖先单倍型A01DR03。

人类白细胞抗原-DQA_1等位基因对少年型重症肌无力的疾病易感性研究

目的 研究人类白细胞抗原 -DQA1(HLA -DQA1)等位基因对少年型重症肌无力的疾病易感性。方法 采用PCR -RFLP方法 ,对 40例少年型重症肌无力患儿的HLA -DQA1基因进行分型 ,并与健康对照组进行比较。结果 DQA1 0 30 1基因的频率在患病组中升高 ,与健康对照组相比表现出显著性差异 (OR =12 33,P <0 0 1) ;DQA1 0 5 0 1的频率降低。结论 HLA -DQA1 0 30 1基因为少年型重症肌无力的易感基因 。

人类白细胞抗原新等位基因B＊54：09的序列分析

目的鉴定1名中国人白细胞抗原（human leukocyte antigen，HLA）新等位基因。方法应用基于Luminex平台的聚合酶链反应一序列特异性寡核苷酸探针（polymerase chain reaction-sequence specific oligonucleotide probes，PCR-SSOP）方法对先证者进行HLA基因分型、PCR产物测序和基因克隆DNA测序，通过软件分析该基因序列并与同源性最高的HLA等位基因比较序列差异。结果PCRSSOP基因分型显示先证者HLA-B位点反应格局异常，疑为HLA新等位基因。基因克隆后测序结果显示，其中1个等位基因为B＊59：01，另一个等位基因序列与所有已知HLA等位基因不同，与同源性最高的HLA-B＊54：06基因序列相比，在第3外显子有6个核苷酸不同（nt486G→C、nt527A→T、nt538T→C、nt539G→T、nt559 C→A和nt560 T→C），导致了3个氨基酸改变，152位氨基酸由GI→Val，156位氨基酸Trp→LeH和163位氨基酸Leu→Thr。结论该等位基因为HLA新等位基因，被世界卫生组织HLA因子命名委员会正式命名为HLAB＊54：09。